Gilead Sciences to Acquire MYR GmbH
One of the largest trade sales of a VC-financed German biotech start-up in the last 20 years - first HTGF unicorn
11-Dec-2020 -
Gilead Sciences, Inc. and MYR GmbH announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 bn in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €0.3 bn million (both ...
acquisitions
GILEAD Sciences
hepatitis